Here are five things to know:
1. K2M filed to halt Stryker’s $1.4 billion acquisition of the company, stating the deal did not disclose correct financial values.
2. On Oct. 22, K2M mollified the investors who filed the lawsuit to block the acquisition through the release of detailed financial projections and statements.
3. In the settlement, K2M stated it “believes that the actions are without merit and that no further disclosure is required.”
4. K2M shareholders are expected to vote on the acquisition Nov. 7 after Stryker pushed the deadline to Nov. 16.
5. Stryker will pay $27.50 per share, a 27 percent premium on K2M’s closing price that ended Aug. 29.
More articles on devices and implants:
3 things to know about Viseon Spine
Medacta appoints general manager of U.S. spine division: 3 insights
Medtronic, DePuy Synthes & more: 11 device company launches, releases
